



INDO-BANGLA PHARMACEUTICALS LIMITED

Corporate Office:

Plot-183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road,
Bashundhara R/A, Dhaka-1229.

Factory: 729, College Road, Barishal-8200.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals Limited (“Company”) in its meeting held on Thursday 30th January, 2025 at 4:00 p.m. at the corporate office, has approved the Un-Audited Financial Statements for the Second Quarter (Q2) period ended on 31th December, 2024.

The key financial highlights for the Second Quarter ended 31th December, 2024 are appended below:

Particulars	As at 31.12.2024	As at 30.06.2024
Net Asset Value (NAV) Per Share	Tk. 13.53	Tk. 13.60

Particulars	July to December 2024	July to December 2023	October to December 2024	October to December 2023
Earnings Per Share (EPS)	Tk. (0.08)	Tk. (0.05)	Tk.(0.05)	Tk. (0.06)
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.03	Tk. 0.23	-	-

The reasons for significant deviation:

- Net Sales Revenue during the period has decreased by 61.62% from Tk. 143,350,591 to Tk. 55,026,290 as compared to the same period of the previous year due to limitation of opening L/C to import raw materials which hampered production and also rising price of the dollar is further increasing import costs, leading to decline the demand of products in the market.
- **Earnings Per Share (EPS)** has been decreased compared to the same period of the previous year due to decreased sales revenue.
- **NOCFPS** has been decreased due to decrease in supplier's payment during the reporting period.
- **NAVPS** has also been decreased due to net loss after tax.

By order of the Board of Directors

-sd-

(Mohi Uddin QCS)

Company Secretary

The details of the published Second Quarter (Q2) Financial Statements are available in the website of the company: www.indo-banglapharma.com.